Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1956 2
1958 2
1960 1
1961 1
1964 1
1965 1
1966 1
1970 2
1974 1
1975 1
1976 4
1978 3
1980 2
1981 2
1982 2
1983 4
1984 2
1985 3
1986 1
1987 3
1988 2
1989 8
1990 2
1991 3
1992 1
1993 4
1995 4
1996 3
1997 7
1998 2
1999 5
2000 2
2001 4
2002 2
2003 5
2004 1
2005 4
2006 5
2008 4
2009 3
2010 2
2011 3
2012 1
2013 2
2014 1
2015 2
2018 1
2020 1
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J, Barber V, Cureton L, Francis A, Appelbe D, Eldridge L, Julier P, Valdes AM, Brooks T, Rombach I, Altmann DM, Nguyen-Van-Tam JS, Williams HC, Cook JA; VROOM study investigators. Abhishek A, et al. Lancet Respir Med. 2022 Sep;10(9):840-850. doi: 10.1016/S2213-2600(22)00186-2. Epub 2022 Jun 27. Lancet Respir Med. 2022. PMID: 35772416 Free PMC article. Clinical Trial.
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, Barber V, Williams JAE, Appelbe D, Eldridge L, Julier P, Altmann DM, Bluett J, Brooks T, Coates LC, Rombach I, Semper A, Otter A, Valdes AM, Nguyen-Van-Tam JS, Williams HC, Boyton RJ, McKnight Á, Cook JA; VROOM study investigators. Abhishek A, et al. Lancet Rheumatol. 2024 Feb;6(2):e92-e104. doi: 10.1016/S2665-9913(23)00298-9. Epub 2023 Dec 12. Lancet Rheumatol. 2024. PMID: 38267107 Free article. Clinical Trial.
Toward a new reference method for the leukocyte five-part differential.
Hübl W, Wolfbauer G, Andert S, Thum G, Streicher J, Hübner C, Lapin A, Bayer PM. Hübl W, et al. Among authors: lapin a. Cytometry. 1997 Apr 15;30(2):72-84. doi: 10.1002/(sici)1097-0320(19970415)30:2<72::aid-cyto2>3.0.co;2-f. Cytometry. 1997. PMID: 9149914 Free article.
Antibodies against oxidized LDL--theory and clinical use.
Steinerová A, Racek J, Stozický F, Zima T, Fialová L, Lapin A. Steinerová A, et al. Among authors: lapin a. Physiol Res. 2001;50(2):131-41. Physiol Res. 2001. PMID: 11522041 Free article. Review.
N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model.
Hoveyda HR, Fraser GL, Zoute L, Dutheuil G, Schils D, Brantis C, Lapin A, Parcq J, Guitard S, Lenoir F, Bousmaqui ME, Rorive S, Hospied S, Blanc S, Bernard J, Ooms F, McNelis JC, Olefsky JM. Hoveyda HR, et al. Among authors: lapin a. Bioorg Med Chem. 2018 Oct 1;26(18):5169-5180. doi: 10.1016/j.bmc.2018.09.015. Epub 2018 Sep 18. Bioorg Med Chem. 2018. PMID: 30253886
Puzzling jaundice.
Reynolds TB, Lapin AC, Peters RL, Yamahiro HS. Reynolds TB, et al. Among authors: lapin ac. JAMA. 1970 Jan 5;211(1):86-90. JAMA. 1970. PMID: 5466896 No abstract available.
128 results